AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26974418 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine with epinephrine
Number of subjects: 120
Study 26974418 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine with epinephrine-bupivicaine mixture
Number of subjects: 120
Study 23971894 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescription opioid misuse
Number of subjects: 515
Study 23465653 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (5 mg IV over 5 min on commencement of bypass then 5 mg IV qid for 24h then 25-50 mg tds orally until discharge)
Number of subjects: 215
Study 23465653 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined metoprolol and amiodarone (300 mg over 1h starting shortly after the commencement of bypass, then 900 mg over 24h then 400 mg orally tds until discharge)
Number of subjects: 215
Study 23465653 — intervention group
Group type: COMPARATOR
Intervention: Control (standard therapy)
Number of subjects: 215
Study 19876659 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive approach
Number of subjects: 59
Study 19876659 — intervention group
Group type: COMPARATOR
Intervention: Conventional open approach
Number of subjects: 59
Study 18813410 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection plus physiotherapy
Number of subjects: 92
Study 18813410 — intervention group
Group type: EXPERIMENTAL
Intervention: Brace plus physiotherapy
Number of subjects: 92
Study 18813410 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Number of subjects: 92
Study 18813410 — intervention group
Group type: EXPERIMENTAL
Intervention: Brace injection
Number of subjects: 92
Study 18813410 — intervention group
Group type: COMPARATOR
Intervention: Bracing
Number of subjects: 92
Study 18813410 — intervention group
Group type: COMPARATOR
Intervention: Injection alone
Number of subjects: 92
Study 16368830 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural neostigmine infusion (500 microg bolus before anesthesia induction, followed by 125 microg/h until end of surgery)
Number of subjects: 90
Study 16368830 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural neostigmine infusion (500 microg bolus at end of surgery)
Number of subjects: 90
Study 16368830 — intervention group
Group type: COMPARATOR
Intervention: Control group received saline placebo during all three periods
Number of subjects: 90
Study 16368830 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural neostigmine infusion (500 microg bolus before anesthesia induction)
Number of subjects: 90
Study 14561539 — intervention group
Group type: EXPERIMENTAL
Intervention: Implanon (etonogestrel 68 mg, single‐rod)
Number of subjects: 80
Study 14561539 — intervention group
Group type: COMPARATOR
Intervention: Norplant (levonorgestrel 36 mg, six capsules)
Number of subjects: 80
Study 10773143 — intervention group
Group type: EXPERIMENTAL
Intervention: Omentoplasty (OP)
Number of subjects: 167
Study 10773143 — intervention group
Group type: COMPARATOR
Intervention: No Omentoplasty (NO)
Number of subjects: 167
Study 2310661 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nisoldipine
Number of subjects: 9
Study 2310661 — intervention group
Group type: COMPARATOR
Intervention: Intravenous hydralazine
Number of subjects: 9
Study 380737 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (7-day course)
Number of subjects: 0
Study 380737 — intervention group
Group type: COMPARATOR
Intervention: Povidone-iodine spray
Number of subjects: 0
Study 31418516 — intervention group
Group type: EXPERIMENTAL
Intervention: Add-on insulin therapy
Number of subjects: 253
Study 29078817 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose pitavastatin (4 mg)
Number of subjects: 500
Study 29078817 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin (20 mg)
Number of subjects: 500
Study 25377166 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal route (trainees)
Number of subjects: 100
Study 25377166 — intervention group
Group type: COMPARATOR
Intervention: Oral route (trainees)
Number of subjects: 100
Study 25377166 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal route (experts)
Number of subjects: 100
Study 25377166 — intervention group
Group type: COMPARATOR
Intervention: Oral route (experts)
Number of subjects: 100
Study 24339307 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 0.5%
Number of subjects: 50
Study 24339307 — intervention group
Group type: COMPARATOR
Intervention: Levofloxacin 0.5%
Number of subjects: 50
Study 22888611 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily iron supplementation
Number of subjects: 370
Study 22888611 — intervention group
Group type: COMPARATOR
Intervention: Twice weekly iron supplementation
Number of subjects: 370
Study 19325449 — intervention group
Group type: EXPERIMENTAL
Intervention: PHiD-CV
Number of subjects: 1650
Study 19325449 — intervention group
Group type: COMPARATOR
Intervention: 7vCRM
Number of subjects: 1650
Study 17257177 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group I, n = 25)
Number of subjects: 75
Study 17257177 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 1200 mg (Group II, n = 25)
Number of subjects: 75
Study 17257177 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 1200 mg and 20 mg/kg paracetamol (Group III, n = 25)
Number of subjects: 75
Study 17257177 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (Group II) and Gabapentin + Paracetamol (Group III)
Number of subjects: 75
Study 17257177 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 1200 mg (Group II) and Gabapentin + Paracetamol (Group III)
Number of subjects: 75
Study 17257177 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group I)
Number of subjects: 75
Study 15838188 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-session intervention
Number of subjects: 1168
Study 15838188 — intervention group
Group type: EXPERIMENTAL
Intervention: Six-session enhanced intervention
Number of subjects: 1168
Study 15838188 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 1168
Study 11961238 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF (1 microg/kg IV)
Number of subjects: 8
Study 11961238 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF (5 microg/kg IV)
Number of subjects: 8
Study 11961238 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone (1 mg/kg twice daily)
Number of subjects: 8
Study 11961238 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 9719736 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminder cards sent to defaulters
Number of subjects: 0
Study 9719736 — intervention group
Group type: EXPERIMENTAL
Intervention: Assistance of patients by lay health workers
Number of subjects: 0
Study 9719736 — intervention group
Group type: EXPERIMENTAL
Intervention: Monetary incentives offered to patients
Number of subjects: 0
Study 9719736 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased supervision of TB clinic staff
Number of subjects: 0
Study 9719736 — intervention group
Group type: COMPARATOR
Intervention: Health education
Number of subjects: 0
Study 9719736 — intervention group
Group type: COMPARATOR
Intervention: Directly-observed therapy (DOT)
Number of subjects: 0
Study 9098476 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of cyproterone acetate and 20 mg of ethynyl‐estradiol in an inversal sequential scheme for six months
Number of subjects: 20
Study 2478788 — intervention group
Group type: EXPERIMENTAL
Intervention: UD‐CG 115 BS 5 mg p.o.
Number of subjects: 25
Study 2478788 — intervention group
Group type: EXPERIMENTAL
Intervention: UD‐CG 115 BS 10 mg p.o.
Number of subjects: 25
Study 2478788 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous treatment with 10 mg of UD‐CG 115 BS/day over 5 days
Number of subjects: 25
Study 2478788 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine (optimal dose)
Number of subjects: 25
Study 6993122 — intervention group
Group type: EXPERIMENTAL
Intervention: Early operation (n=28)
Number of subjects: 60
Study 6993122 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment followed by delayed operation (n=30)
Number of subjects: 60
Study 6993122 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (early operation and delayed operation)
Number of subjects: 60
Study 31680331 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 g fibrinogen concentrate
Number of subjects: 0
Study 28228426 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic (Lactobacillus gasseri KS-13, Bifidobacterium bifidum G9-1, and Bifidobacterium longum MM-2) 2 capsules/d, 1.5 billion colony-forming units/capsule for 8 weeks
Number of subjects: 173
Study 28228426 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173
Study 25755079 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (Zn group)
Number of subjects: 84
Study 25755079 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 84
Study 24628943 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 152
Study 24628943 — intervention group
Group type: COMPARATOR
Intervention: Nicotine patch
Number of subjects: 152
Study 24628943 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study 22464209 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of embryo culture supernatant before embryo transfer
Number of subjects: 400
Study 19924786 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 120
Study 19924786 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery and radiotherapy
Number of subjects: 120
Study 19924786 — intervention group
Group type: EXPERIMENTAL
Intervention: Definitive radiotherapy
Number of subjects: 120
Study 19924786 — intervention group
Group type: EXPERIMENTAL
Intervention: No local therapy
Number of subjects: 120
Study 19924786 — intervention group
Group type: EXPERIMENTAL
Intervention: Local treatment of both primary tumor and metastases
Number of subjects: 120
Study 19924786 — intervention group
Group type: EXPERIMENTAL
Intervention: Any local treatment of either primary tumor or metastases
Number of subjects: 120
Study 19924786 — intervention group
Group type: COMPARATOR
Intervention: Absence of local treatment
Number of subjects: 120
Study 18608312 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-session protocol emphasizing values-based exposure and acceptance strategies
Number of subjects: 21
Study 18608312 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 21
Study 16043009 — intervention group
Group type: EXPERIMENTAL
Intervention: Home palliative care program
Number of subjects: 159
Study 16043009 — intervention group
Group type: COMPARATOR
Intervention: No access to home palliative care program
Number of subjects: 159
Study 12184365 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous (s.q.) administration of AVA
Number of subjects: 0
Study 10522995 — intervention group
Group type: EXPERIMENTAL
Intervention: MENT (7alpha‐methyl‐19‐nortestosterone)
Number of subjects: 20
Study 10522995 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (TE)
Number of subjects: 20
Study 10522995 — intervention group
Group type: EXPERIMENTAL
Intervention: MENT
Number of subjects: 20
Study 10522995 — intervention group
Group type: COMPARATOR
Intervention: Wash-out phase
Number of subjects: 20
Study 8534466 — intervention group
Group type: EXPERIMENTAL
Intervention: 70% N2O in 30% O2 administered by face mask for 120 seconds
Number of subjects: 50
Study 8534466 — intervention group
Group type: COMPARATOR
Intervention: 2.5 g of EMLA cream under an occlusive dressing for a minimum of 60 minutes
Number of subjects: 50
Study 2178535 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine, 300 mg orally, administered 1 hour before running
Number of subjects: 14
Study 2178535 — intervention group
Group type: COMPARATOR
Intervention: Placebo, administered after a low-fat breakfast before baseline pH recording
Number of subjects: 14
Study 6121762 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg
Number of subjects: 9
Study 6121762 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 160 mg
Number of subjects: 9
Study 6121762 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 6121762 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (various doses)
Number of subjects: 9
Study 31109110 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle modification (3-month one-on-one intervention)
Number of subjects: 123
Study 31109110 — intervention group
Group type: COMPARATOR
Intervention: Standard guidance (control group)
Number of subjects: 123
Study 27839664 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic taping
Number of subjects: 26
Study 27839664 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo taping
Number of subjects: 26
Study 27839664 — intervention group
Group type: COMPARATOR
Intervention: No taping
Number of subjects: 26
Study 25967983 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based psychoeducational program (Diapason) for 3 months
Number of subjects: 49
Study 25967983 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 49
Study 23711165 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (more extensive advice and frequent follow-up)
Number of subjects: 133
Study 23711165 — intervention group
Group type: COMPARATOR
Intervention: Control group (ordinary care)
Number of subjects: 133
Study 23711165 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 133
Study 23711165 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 133
Study 22068744 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold water immersion (0-2°C) for 50 seconds
Number of subjects: 2
Study 22068744 — intervention group
Group type: COMPARATOR
Intervention: Room temperature water immersion (22-24°C) for 50 seconds
Number of subjects: 2
Study 19864219 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone
Number of subjects: 0
Study 19864219 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol
Number of subjects: 0
Study 19864219 — intervention group
Group type: COMPARATOR
Intervention: Air pollution (NO2 and PM10)
Number of subjects: 0
Study 17533210 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal model (age, sex, parental history of diabetes, body mass index)
Number of subjects: 160
Study 17533210 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple clinical model (including parental history of diabetes, obesity, hypertension, low HDL cholesterol, elevated triglycerides, impaired fasting glucose)
Number of subjects: 160
Study 17533210 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex clinical models (including 2-hour post-OGTT glucose, fasting insulin, C-reactive protein, Gutt insulin sensitivity index, homeostasis model insulin resistance)
Number of subjects: 160
Study 15570070 — intervention group
Group type: EXPERIMENTAL
Intervention: Marimastat (10 mg bid)
Number of subjects: 179
Study 15570070 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179
Study 15570070 — intervention group
Group type: EXPERIMENTAL
Intervention: Marimastat (10 mg bid) with plasma concentration ≥ 10 ng/mL
Number of subjects: 179
Study 15570070 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade 2 or 3 MST
Number of subjects: 179
Study 15570070 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade 0 or 1 MST
Number of subjects: 179
Study 11222071 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadolinium-enhanced magnetic resonance angiography (Gd-MRA)
Number of subjects: 17
Study 11222071 — intervention group
Group type: COMPARATOR
Intervention: Digital subtraction angiography (DSA)
Number of subjects: 17
Study 9458569 — intervention group
Group type: EXPERIMENTAL
Intervention: Video about infant immunization
Number of subjects: 227
Study 9458569 — intervention group
Group type: COMPARATOR
Intervention: Oral presentation about infant immunization
Number of subjects: 227
Study 8169430 — intervention group
Group type: EXPERIMENTAL
Intervention: 360 ELISA units (EU)
Number of subjects: 80
Study 8169430 — intervention group
Group type: EXPERIMENTAL
Intervention: 720 ELISA units (EU)
Number of subjects: 80
Study 8169430 — intervention group
Group type: EXPERIMENTAL
Intervention: 1440 ELISA units (EU)
Number of subjects: 80
Study 8169430 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses after two injections
Number of subjects: 80
Study 8169430 — intervention group
Group type: EXPERIMENTAL
Intervention: 0-, 2-, and 4-month schedule
Number of subjects: 80
Study 8169430 — intervention group
Group type: COMPARATOR
Intervention: 0-, 1-, and 6-month schedule
Number of subjects: 80
Study 8169430 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month schedule
Number of subjects: 80
Study 3280617 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiothixene
Number of subjects: 29
Study 3280617 — intervention group
Group type: COMPARATOR
Intervention: Chlorpromazine
Number of subjects: 29
Study 30645153 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g IV acetaminophen
Number of subjects: 86
Study 30645153 — intervention group
Group type: COMPARATOR
Intervention: IV placebo
Number of subjects: 86
Study 28438182 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced fluid removal with a therapeutic target of negative net fluid balance ≥1 mL/kg/h
Number of subjects: 0
Study 28438182 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 28438182 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced fluid removal
Number of subjects: 0
Study 25346373 — intervention group
Group type: EXPERIMENTAL
Intervention: T-GLY
Number of subjects: 6
Study 25346373 — intervention group
Group type: EXPERIMENTAL
Intervention: CHX-GLY
Number of subjects: 6
Study 25346373 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-GLY
Number of subjects: 6
Study 25346373 — intervention group
Group type: EXPERIMENTAL
Intervention: T-PC
Number of subjects: 6
Study 25346373 — intervention group
Group type: EXPERIMENTAL
Intervention: PW-GLY
Number of subjects: 6
Study 25346373 — intervention group
Group type: EXPERIMENTAL
Intervention: PW-PC
Number of subjects: 6
Study 25346373 — intervention group
Group type: EXPERIMENTAL
Intervention: CHX-PC
Number of subjects: 6
Study 25346373 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-PC
Number of subjects: 6
Study 22560371 — intervention group
Group type: EXPERIMENTAL
Intervention: D-cycloserine (50mg once weekly)
Number of subjects: 29
Study 22560371 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-behavioral therapy
Number of subjects: 29
Study 22560371 — intervention group
Group type: COMPARATOR
Intervention: D-cycloserine (0mg, placebo)
Number of subjects: 29
Study 22560371 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 29
Study 20664274 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab treatment
Number of subjects: 19
Study 20664274 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 19
Study 17701037 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine 400 mg/m2 (dose level 0)
Number of subjects: 12
Study 17701037 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine 200 mg/m2 (dose level -1)
Number of subjects: 12
Study 17701037 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-hematologic toxicity
Number of subjects: 12
Study 17701037 — intervention group
Group type: EXPERIMENTAL
Intervention: Hematologic toxicity at dose level 0
Number of subjects: 12
Study 16089221 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide (H2O2) mouth rinse
Number of subjects: 37
Study 16089221 — intervention group
Group type: COMPARATOR
Intervention: Water rinse (control)
Number of subjects: 37
Study 12613268 — intervention group
Group type: EXPERIMENTAL
Intervention: Esberitox N (herbal immunomodulator), dosage: 3 x 2 tablets daily, duration: from 3 days prior to injection to 2 weeks after injection
Number of subjects: 346
Study 12613268 — intervention group
Group type: COMPARATOR
Intervention: Placebo, dosage: 3 x 2 tablets daily, duration: from 3 days prior to injection to 2 weeks after injection
Number of subjects: 346
Study 11910665 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE therapy (0.625 mg/day of conjugated equine estrogen)
Number of subjects: 134
Study 11910665 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE/MPA therapy (0.625 mg/day of CEE and 2.5 mg/day of medroxyprogesterone acetate)
Number of subjects: 134
Study 11910665 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study 8730943 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants and behavioural counselling
Number of subjects: 68
Study 1924235 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular administration of 10% isoniazid solution
Number of subjects: 126
Study 1924235 — intervention group
Group type: COMPARATOR
Intervention: Oral isoniazid
Number of subjects: 126
Study 7110846 — intervention group
Group type: EXPERIMENTAL
Intervention: Footrest vibration
Number of subjects: 16
Study 7110846 — intervention group
Group type: EXPERIMENTAL
Intervention: Backrest vibration
Number of subjects: 16
Study 7110846 — intervention group
Group type: EXPERIMENTAL
Intervention: Footrest-backrest vibration combined
Number of subjects: 16
Study 7110846 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 16
Study 30421573 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-based screening with Abbot RealTime hrHPV test and cytology triage
Number of subjects: 46708
Study 30421573 — intervention group
Group type: COMPARATOR
Intervention: Conventional Pap cytology screening
Number of subjects: 46708
Study 30550174 — intervention group
Group type: EXPERIMENTAL
Intervention: MoCA (Montreal Cognitive Assessment)
Number of subjects: 72
Study 30550174 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum NPY levels
Number of subjects: 72
Study 30550174 — intervention group
Group type: COMPARATOR
Intervention: Control group re-testing of MoCA
Number of subjects: 72
Study 27021451 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticotomy
Number of subjects: 20
Study 27021451 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezocision
Number of subjects: 20
Study 27021451 — intervention group
Group type: COMPARATOR
Intervention: Control (contralateral sides)
Number of subjects: 20
Study 24933729 — intervention group
Group type: EXPERIMENTAL
Intervention: Seven types of orthotic materials
Number of subjects: 0
Study 24933729 — intervention group
Group type: EXPERIMENTAL
Intervention: Material brand, density, cell volume, and thickness of orthotic materials
Number of subjects: 0